ESTA Reiterated by TD Cowen -- Price Target Maintained at $117
TD Cowen reaffirmed a 'Buy' rating and $117 price target for Establishment Labs (ESTA). The stock is trading at a 9.0% discount to its GF Value™ of $65.35. ESTA has a GF Score™ of 78/100, indicating strong growth and valuation metrics, but weaker financial strength and profitability. 4 gurus hold positions, with 3 adding recently.
How this was made
The 30-second read
Why it matters
Analyst reaffirmation may prompt short‑term buying, but the lack of new operational news limits broader market impact.
Market read
Company‑specific analyst rating update with modest trading relevance.
What to watch
Potential regulatory risks and the need for continued product approvals could limit upside.
Background
TD Cowen analysts maintain a Buy stance on ESTA, a medical‑technology firm specializing in silicone breast implants, with a $117 price target.
Ticker impact
TD Cowen reaffirmed a Buy rating on ESTA and kept the price target at $117, providing a fresh analyst endorsement.
likely upward pressure as the market prices in the unchanged $117 target
Analyst reaffirmation with a specific price target can attract short-term interest, but no new catalyst beyond the rating change.
Market effects
Reinforces positive sentiment for the medical device sector, but impact is limited to ESTA.
Minimal, primarily U.S. equity market.
Low, as the news is company‑specific.
Counterpoint
The rating may be overly optimistic given ESTA's unprofitability and cash‑flow challenges.
Key entities
- Analyst FirmTD Cowen
Provided the reaffirmed Buy rating and price target.
- CompanyEstablishment Labs Holdings Inc.
Subject of the rating update.
